Vol 2004, No 53 (2004)

Table of Contents

Research & Development

Novartis Validates Xenon and its Obesity Programme with US$157 M Deal Abstract pdf
Business Review Editor
Gilead and Genelabs Form Hepatitis C Alliance Abstract pdf
Business Review Editor

Licensing

Forest Labs Licenses Respiratory Drug from Glenmark Abstract pdf
Business Review Editor
Nastech and Merck to Co-Develop Nasal Spray for Obesity Abstract pdf
Business Review Editor

General

Aradigm’s Confidence Boosted by Novo Nordisk Abstract
Business Review Editor

Company Profile

TopoTarget AS Abstract pdf
Business Review Editor
Xerion Pharmaceuticals AG Abstract pdf
Business Review Editor

Distribution & Marketing

ISTA and Allergan in New Vitrase® Collaboration Abstract pdf
Business Review Editor

Business Commentaries

Alliances are Forever? html
Fintan Walton

Deal Trackers

Raptiva (efalizumab) Abstract pdf
Business Review Editor

Mergers & Acquisitions

Exelixis to Merge with X-Ceptor Therapeutics Abstract pdf
Business Review Editor


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.